Logo image of CANB.CA

CANADABIS CAPITAL INC (CANB.CA) Stock Fundamental Analysis

TSX-V:CANB - TSX Venture Exchange - CA13530Q1046 - Common Stock - Currency: CAD

0.04  0 (-11.11%)

Fundamental Rating

3

Taking everything into account, CANB scores 3 out of 10 in our fundamental rating. CANB was compared to 35 industry peers in the Pharmaceuticals industry. While CANB is still in line with the averages on profitability rating, there are concerns on its financial health. CANB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

In the past year CANB has reported negative net income.
In the past year CANB has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: CANB reported negative net income in multiple years.
In the past 5 years CANB reported 4 times negative operating cash flow.
CANB.CA Yearly Net Income VS EBIT VS OCF VS FCFCANB.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M

1.2 Ratios

With a decent Return On Assets value of 0.28%, CANB is doing good in the industry, outperforming 77.14% of the companies in the same industry.
The Return On Equity of CANB (0.81%) is better than 77.14% of its industry peers.
With a decent Return On Invested Capital value of 2.07%, CANB is doing good in the industry, outperforming 68.57% of the companies in the same industry.
CANB had an Average Return On Invested Capital over the past 3 years of 13.87%. This is significantly above the industry average of 7.79%.
The last Return On Invested Capital (2.07%) for CANB is well below the 3 year average (13.87%), which needs to be investigated, but indicates that CANB had better years and this may not be a problem.
Industry RankSector Rank
ROA 0.28%
ROE 0.81%
ROIC 2.07%
ROA(3y)8.58%
ROA(5y)-7.49%
ROE(3y)30.91%
ROE(5y)-44.74%
ROIC(3y)13.87%
ROIC(5y)N/A
CANB.CA Yearly ROA, ROE, ROICCANB.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

CANB's Profit Margin of 0.41% is fine compared to the rest of the industry. CANB outperforms 68.57% of its industry peers.
CANB has a better Operating Margin (3.03%) than 71.43% of its industry peers.
CANB's Gross Margin of 46.57% is fine compared to the rest of the industry. CANB outperforms 71.43% of its industry peers.
CANB's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 3.03%
PM (TTM) 0.41%
GM 46.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.23%
GM growth 5YN/A
CANB.CA Yearly Profit, Operating, Gross MarginsCANB.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), CANB is creating some value.
CANB has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, CANB has more shares outstanding
CANB has a better debt/assets ratio than last year.
CANB.CA Yearly Shares OutstandingCANB.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CANB.CA Yearly Total Debt VS Total AssetsCANB.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of 0.58, we must say that CANB is in the distress zone and has some risk of bankruptcy.
CANB has a better Altman-Z score (0.58) than 68.57% of its industry peers.
A Debt/Equity ratio of 1.07 is on the high side and indicates that CANB has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.07, CANB is doing worse than 74.29% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF N/A
Altman-Z 0.58
ROIC/WACC0.25
WACC8.15%
CANB.CA Yearly LT Debt VS Equity VS FCFCANB.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

CANB has a Current Ratio of 1.58. This is a normal value and indicates that CANB is financially healthy and should not expect problems in meeting its short term obligations.
CANB's Current ratio of 1.58 is in line compared to the rest of the industry. CANB outperforms 54.29% of its industry peers.
A Quick Ratio of 0.33 indicates that CANB may have some problems paying its short term obligations.
CANB has a Quick ratio of 0.33. This is amonst the worse of the industry: CANB underperforms 88.57% of its industry peers.
Industry RankSector Rank
Current Ratio 1.58
Quick Ratio 0.33
CANB.CA Yearly Current Assets VS Current LiabilitesCANB.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

2

3. Growth

3.1 Past

The earnings per share for CANB have decreased strongly by -97.47% in the last year.
Looking at the last year, CANB shows a decrease in Revenue. The Revenue has decreased by -8.85% in the last year.
The Revenue has been growing by 37.77% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-97.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-125%
Revenue 1Y (TTM)-8.85%
Revenue growth 3Y37.77%
Revenue growth 5YN/A
Sales Q2Q%-18.46%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CANB.CA Yearly Revenue VS EstimatesCANB.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

Industry RankSector Rank
PE N/A
Fwd PE N/A
CANB.CA Price Earnings VS Forward Price EarningsCANB.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

74.29% of the companies in the same industry are more expensive than CANB, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 9.23
CANB.CA Per share dataCANB.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 0.1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CANB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CANADABIS CAPITAL INC

TSX-V:CANB (8/6/2025, 7:00:00 PM)

0.04

0 (-11.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)06-30 2025-06-30
Earnings (Next)11-26 2025-11-26
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners53.52%
Ins Owner ChangeN/A
Market Cap5.52M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.32
P/FCF N/A
P/OCF N/A
P/B 0.64
P/tB 0.64
EV/EBITDA 9.23
EPS(TTM)0
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.12
BVpS0.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.28%
ROE 0.81%
ROCE 3.3%
ROIC 2.07%
ROICexc 2.18%
ROICexgc 2.18%
OM 3.03%
PM (TTM) 0.41%
GM 46.57%
FCFM N/A
ROA(3y)8.58%
ROA(5y)-7.49%
ROE(3y)30.91%
ROE(5y)-44.74%
ROIC(3y)13.87%
ROIC(5y)N/A
ROICexc(3y)16.34%
ROICexc(5y)N/A
ROICexgc(3y)16.34%
ROICexgc(5y)N/A
ROCE(3y)24.27%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.23%
GM growth 5YN/A
F-Score2
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF N/A
Debt/EBITDA 6.6
Cap/Depr 19.78%
Cap/Sales 1.03%
Interest Coverage 1.29
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.58
Quick Ratio 0.33
Altman-Z 0.58
F-Score2
WACC8.15%
ROIC/WACC0.25
Cap/Depr(3y)74.66%
Cap/Depr(5y)403.75%
Cap/Sales(3y)2.7%
Cap/Sales(5y)24.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-97.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-125%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-8.85%
Revenue growth 3Y37.77%
Revenue growth 5YN/A
Sales Q2Q%-18.46%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-80.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-173.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-157.84%
OCF growth 3YN/A
OCF growth 5YN/A